{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001723128","name":"Amneal Pharmaceuticals, Inc.","summary":"Amneal Pharmaceuticals, Inc. is a diversified global biopharmaceutical company that develops, manufactures, markets, and distributes essential medicines across three segments: Affordable Medicines (retail generics, injectables, biosimilars), Specialty (branded pharmaceuticals focused on CNS and endocrine disorders, including CREXONT for Parkinson's disease), and AvKARE (distributor of pharmaceuticals for U.S. federal government, retail, and institutional markets). The company operates principally in the United States, India, and Ireland.","people":[],"products":[{"name":"CREXONT","type":"hardware","description":"Carbidopa and levodopa extended-release capsules for treatment of Parkinson's disease in the United States"},{"name":"ONGENTYS (opicapone)","type":"service","description":"Once-daily catechol-O-methyltransferase inhibitor for Parkinson's disease patients experiencing off episodes, licensed from BIAL"},{"name":"IPX203","type":"hardware","description":"Parkinson's disease product licensed to Zambon for Europe and Knight for Canada/Latin America; marketed as CREXONT in U.S."},{"name":"Generic Pharmaceuticals Portfolio","type":"hardware","description":"Over 280 product families including oral solids, injectables, biosimilars, nasal sprays, transdermal patches, and ophthalmics"},{"name":"Carfilzomib","type":"hardware","description":"Generic oncology product candidate licensed from Kashiv for development and commercialization in the U.S."}],"partnerships":[{"partner_name":"ApiJect Systems, Corp.","partnership_type":"strategic","description":"15-year collaboration to install and operate blow fill seal manufacturing equipment at Amneal's Brookhaven, NY facility for injectable products","start_date":null},{"partner_name":"Metsera, Inc. (acquired by Pfizer)","partnership_type":"development","description":"Collaboration making Amneal preferred global supply partner for weight loss medicines; exclusive commercialization rights in select emerging markets","start_date":null},{"partner_name":"Zambon Biotech S.A.","partnership_type":"licensing","description":"15-year license, distribution and supply agreement granting Zambon exclusive rights to commercialize IPX203 in Europe","start_date":null},{"partner_name":"Knight Therapeutics International S.A.","partnership_type":"licensing","description":"15-year license, distribution and supply agreement granting Knight exclusive rights to commercialize IPX203 in Canada and Latin America","start_date":null},{"partner_name":"BIAL-Portela & Ca., S.A.","partnership_type":"licensing","description":"Exclusive U.S. license to market and distribute ONGENTYS (opicapone); termination notice served effective February 26, 2028","start_date":null},{"partner_name":"Kashiv Biosciences LLC","partnership_type":"development","description":"License and supply agreements covering long-acting injectable and Carfilzomib product candidates for U.S. development and commercialization","start_date":null}],"affiliations":[],"origin":{"leaf":"27868395e270c1931ce40e774c423544c53f616a5b088dd69d22362c7f30e92d","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"573cdfa003cfe9615ea6ccef3cb5e7766ac554101d9208effb3466817f718f99","parent":"8f6fb67817a46cb968560f1ac67d5c8be272fe2b48f7f1854bae20a1f85cf5be","source":"0001723128-26-000011","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":500,"hourly_limit":500,"remaining":0,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}